| P50 | author | Pierluigi Porcu | Q55483096 |
| | Rebecca Kohnken | Q61197732 |
| | Bradley M Haverkos | Q87988147 |
| P2093 | author name string | Alejandro A Gru | |
| | Anjali Mishra | |
| | Justin G Hastings | |
| | Pooja Virmani | |
| | Stephanie K Fabbro | |
| | Steve M Horwitz | |
| | Susan H Hwang | |
| P2860 | cites work | Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers | Q24605342 |
| | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 |
| | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas | Q26774768 |
| | Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion. | Q27853146 |
| | Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 |
| | Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 |
| | Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study | Q33393701 |
| | Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma | Q33400117 |
| | Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study | Q33400977 |
| | Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma | Q33935031 |
| | Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors | Q34052608 |
| | Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code | Q34193936 |
| | Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). | Q34333859 |
| | Changing incidence trends of cutaneous T-cell lymphoma | Q34368699 |
| | Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment | Q34633209 |
| | The CD52 antigen and development of the CAMPATH antibodies | Q34780507 |
| | Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) | Q35022833 |
| | Systematic review of combination therapies for mycosis fungoides | Q35201808 |
| | Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma | Q35222112 |
| | Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients | Q35567170 |
| | Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project | Q35701501 |
| | The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma | Q35750752 |
| | Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. | Q36026719 |
| | Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of | Q36174236 |
| | EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. | Q36436109 |
| | Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome | Q36471121 |
| | Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis | Q36534677 |
| | Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? | Q36913972 |
| | Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach | Q37146595 |
| | Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model | Q37163606 |
| | Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases | Q37201934 |
| | Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma | Q37323004 |
| | Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. | Q37379370 |
| | Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project | Q37384289 |
| | Pralatrexate: basic understanding and clinical development | Q37761372 |
| | Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review | Q38028137 |
| | Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? | Q38196931 |
| | Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature | Q38218948 |
| | Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders | Q38240733 |
| | Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides | Q38813983 |
| | Sézary Syndrome: Clinical and Biological Aspects | Q38814744 |
| | Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. | Q38844903 |
| | Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides | Q38858965 |
| | Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition | Q39253408 |
| | Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma | Q40026998 |
| | Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma | Q40277620 |
| | Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma | Q40764990 |
| | A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides | Q40768413 |
| | The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas | Q40809016 |
| | Immune modulators as therapeutic agents for cutaneous T-cell lymphoma | Q41844919 |
| | Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission | Q41984219 |
| | Genomic landscape of cutaneous T cell lymphoma | Q42027899 |
| | Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides | Q42170297 |
| | Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. | Q42232495 |
| | Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa | Q42471736 |
| | Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up | Q42480934 |
| | Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event | Q42550983 |
| | Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. | Q42882402 |
| | Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma | Q42942114 |
| | Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma | Q43444250 |
| | Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome | Q43543686 |
| | Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly | Q43578719 |
| | Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results | Q43594172 |
| | Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q43597205 |
| | A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma | Q43612578 |
| | Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience | Q44316514 |
| | Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma | Q44990828 |
| | Mycosis fungoides: the addition of concurrent and adjuvant interferon to total skin electron beam therapy | Q45359518 |
| | Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. | Q46061398 |
| | Bexarotene therapy for mycosis fungoides and Sézary syndrome. | Q46119707 |
| | Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. | Q46302590 |
| | A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma | Q46423582 |
| | Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas | Q47654977 |
| | Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. | Q47860803 |
| | Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. | Q51103802 |
| | Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma. | Q52767066 |
| | A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. | Q53109137 |
| | Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. | Q53122623 |
| | Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. | Q53548352 |
| | Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment. | Q53566641 |
| | Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. | Q54524230 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic therapy | Q1929812 |
| P304 | page(s) | 111-121 | |
| P577 | publication date | 2016-12-21 | |
| P1433 | published in | Expert Review of Hematology | Q15734429 |
| P1476 | title | Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? | |
| P478 | volume | 10 | |